title: Celecoxib augmentation of continuously ill patients with schizophrenia.
abstract: BACKGROUND
  Previous reports have demonstrated a beneficial effect of celecoxib adjunctive therapy for patients with an acute exacerbation of schizophrenia. We investigated the effects of celecoxib augmentation of atypical antipsychotic medications for continuously symptomatic outpatient subjects with schizophrenia to further extend these findings. We hypothesized that celecoxib augmentation therapy would improve psychopathology ratings compared with placebo.
  
  
  METHODS
  Thirty-eight symptomatic outpatient subjects meeting DSM-IV criteria for schizophrenia and on a stable dose of an atypical antipsychotic medication for at least three months were randomized to receive 8 weeks of double blind placebo or celecoxib (400 mg/day) augmentation. Measures of psychopathology, functional disability, and extrapyramidal side effects were performed throughout the study.
  
  
  RESULTS
  The treatment cohorts did not differ on any of the clinical outcome measures.
  
  
  CONCLUSIONS
  Celecoxib augmentation of continuously ill outpatient subjects with schizophrenia did not improve clinical symptoms or measures of disability.
authors.affiliation: Department of Psychiatry, Cedars-Sinai Medical Center, Los Angeles; Department of Psychiatry, Geffen School of Medicine, University of California - Los Angeles 90045, USA. mark.rapaport@cshs.org
authors.forename: Mark Hyman
authors.initials: MH
authors.lastname: Rapaport
authors.forename: Katia K
authors.initials: KK
authors.lastname: Delrahim
authors.forename: Catherine J
authors.initials: CJ
authors.lastname: Bresee
authors.forename: Rachel E
authors.initials: RE
authors.lastname: Maddux
authors.forename: Oliver
authors.initials: O
authors.lastname: Ahmadpour
authors.forename: Douglas
authors.initials: D
authors.lastname: Dolnak
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use; D000068579:Celecoxib; D004311:Double-Blind Method; D004357:Drug Synergism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D011720:Pyrazoles / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D013449:Sulfonamides / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D014150:Antipsychotic Agents; D010919:Placebos; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib